STOCK TITAN
  1. Home
  2. News
  3. IMMP

Immutep Limited - IMMP STOCK NEWS

Welcome to our dedicated news page for Immutep (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immutep's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immutep's position in the market.

News
Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer
Rhea-AI Summary
Immutep Limited announces the completion of the open-label safety lead-in phase of its AIPAC-003 Phase II/III trial. The trial evaluated the combination of 90mg eftilagimod alpha (efti) with paclitaxel in six patients with metastatic breast cancer. There were no safety or tolerability issues, and the independent Data Monitoring Committee recommended proceeding to the randomized Phase II portion of the trial. The Phase II portion will include up to 58 evaluable patients to determine the optimal biological dose.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer
Rhea-AI Summary
Immutep Limited announces new biomarker data from the TACTI-002/KEYNOTE-798 Phase II trial, showing statistically significant increases in Th1 biomarkers and immune activating genes. The data supports the success of eftilagimod alpha (efti) in first-line treatment of non-small cell lung cancer (NSCLC) patients. The increase in absolute lymphocyte count (ALC) is correlated with positive overall survival results. Similar immune response biomarkers were seen in the AIPAC Phase IIb trial in metastatic breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
clinical trial
-
News
Immutep to Participate in November Investor Events
Rhea-AI Summary
Immutep Limited announces its management's participation in upcoming investor events in November. The events include Baird's Biotech Discovery Series and Jefferies London Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
conferences
News
Immutep Quarterly Activities Report Q1 FY24
Rhea-AI Summary
Immutep Limited provides an update on the development of its product candidates, including positive survival results in the TACTI-002 trial for non-small cell lung cancer (NSCLC). The trial showed a median Overall Survival of 35.5 months, providing an additional 12-18 months compared to historical data. The company is also progressing in other trials for head and neck squamous cell carcinoma (HNSCC) and metastatic breast cancer (MBC). Immutep has a strong cash position of $110.1 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
none
-
News
Immutep receives ~A$1.13 million R&D Tax Incentive
Rhea-AI Summary
Immutep Limited has received a A$1,134,882 cash rebate from the Australian Federal Government’s R&D tax incentive program. The rebate is for eligible R&D activities conducted in the 2022 fiscal year, specifically related to the TACTI-002 and TACTI-003 clinical studies using its lead compound eftilagimod alpha. Immutep will use the funding to further its current active clinical trial programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.66%
Tags
none
-
News
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
Rhea-AI Summary
Immutep reports promising clinical data from the INSIGHT-003 trial evaluating a triple combination therapy for metastatic non-small cell lung cancer. The therapy showed strong efficacy with a 71.4% Overall Response Rate, 90.5% Disease Control Rate, and a median Progression Free Survival of 10.1 months. The combination also demonstrated positive results in patients with low or negative PD-L1 expression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.39%
Tags
clinical trial
News
Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
Rhea-AI Summary
Immutep Limited announces excellent new clinical data from the TACTI-002 / KEYNOTE-798 Phase II trial evaluating eftilagimod alpha in combination with KEYTRUDA for the treatment of non-small cell lung cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
none
-
News
Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
Rhea-AI Summary
Immutep announces acceptance of abstract for poster presentation at SITC Annual Meeting 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
none
-
News
Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use
Rhea-AI Summary
Immutep achieves comparability of drug substance and product at 2,000L scale for use in clinical trials across Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
clinical trial
News
Immutep to Participate in September Investor Conferences
Rhea-AI Summary
Immutep Limited announces participation in upcoming investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Stock IMMP logo
Immutep Limited

Nasdaq:IMMP

IMMP Rankings

#3379 Ranked by Market Cap
#1726 Ranked by Stock Gains
N/A Ranked by Dividends

IMMP Stock Data

296.02M
1.06B
0.01%
2.77%
1.06%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Australia
Sydney

About IMMP

immutep is a globally active biotechnology company, listed on the australian stock exchange and on the nasdaq global market in the us. as a leader in personalized bio-therapeutic products for cancer, immutep is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. immutep's main pipeline of products is based on the lag-3 immune control mechanism which plays a vital role in the regulation of the t cell immune response. the most clinically advanced product is a t cell immunostimulatory factor (apc activator), imp321, for cancer chemoimmunotherapy which has completed early phase ii trials. a number of additional lag-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.